Literature DB >> 12203792

Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.

Tony Frisk1, Theodoris Foukakis, Trisha Dwight, Jonas Lundberg, Anders Höög, Göran Wallin, Charis Eng, Jan Zedenius, Catharina Larsson.   

Abstract

Germline mutations in the tumor-suppressor gene PTEN (MMAC1, TEP1) are found in Cowden syndrome, which predisposes to hamartomas, breast cancer, trichilemmomas, and thyroid tumors of follicular epithelium. PTEN has also been found to be somatically deleted, mutated, and/or silenced in various sporadically occurring cancers such as glioblastoma, breast cancer, kidney cancer, malignant melanoma, and endometrial cancer. Loss or reduction of PTEN protein expression as well as inappropriate subcellular compartmentalization is seen in non-medullary thyroid cancers. However, although allelic loss of the PTEN locus in 10q23.3 is frequently seen, this is not coupled with mutations in the PTEN gene. To approach further the frequency and mechanism behind PTEN silencing, we screened a panel of 87 sporadic thyroid tumors for PTEN mRNA expression, including 14 anaplastic carcinomas, 37 follicular carcinomas, 21 atypical adenomas, and 15 ordinary adenomas. Complete loss of PTEN mRNA expression was evident in six of the tumors, including four anaplastic carcinomas, one widely invasive carcinoma, and one ordinary adenoma. The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors. No association was observed between the expression, loss of heterozygosity, and mutation status in the 33 cases in which these parameters were compared. This indicates that PTEN silencing is a result of a wide variety of epigenetic and/or structural silencing mechanisms rather than a consequence of structural biallelic inactivation of the classical type. Furthermore, the high rate of alterations in the 10q23 region might indicate the presence of an as-yet unknown tumor-suppressor gene with an important role in the development of thyroid tumors. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203792     DOI: 10.1002/gcc.10098

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  23 in total

Review 1.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

2.  Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer.

Authors:  Getachew Boru; Timothy W Grosel; Robert Pilarski; Meredith Stautberg; James B Massengill; Joanne Jeter; Arun Singh; Meghan J Marino; Joseph P McElroy; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman
Journal:  Genes Chromosomes Cancer       Date:  2019-04-23       Impact factor: 5.006

3.  Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?

Authors:  S Adeleh Razavi; Mohammad Hossein Modarressi; Parichehr Yaghmaei; S Mohammad Tavangar; Mehdi Hedayati
Journal:  Endocrine       Date:  2017-07-28       Impact factor: 3.633

Review 4.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

5.  MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.

Authors:  Julia Ramírez-Moya; León Wert-Lamas; Pilar Santisteban
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

Review 6.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

7.  Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.

Authors:  Shawn D Larson; Lindsey N Jackson; Taylor S Riall; Tatsuo Uchida; Robert P Thomas; Suimin Qiu; B Mark Evers
Journal:  J Am Coll Surg       Date:  2007-02-23       Impact factor: 6.113

8.  Suppression of PTEN expression by NF-kappa B prevents apoptosis.

Authors:  Krishna Murthi Vasudevan; Sushma Gurumurthy; Vivek M Rangnekar
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

9.  FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.

Authors:  Roberto Bellelli; Maria Domenica Castellone; Ginesa Garcia-Rostan; Clara Ugolini; Carmelo Nucera; Peter M Sadow; Tito Claudio Nappi; Paolo Salerno; Maria Carmela Cantisani; Fulvio Basolo; Tomas Alvarez Gago; Giuliana Salvatore; Massimo Santoro
Journal:  Endocr Relat Cancer       Date:  2012-09-21       Impact factor: 5.678

Review 10.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.